Cargando…
Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
PURPOSE: Carfilzomib has been approved for use in relapsed and refractory multiple myeloma (RRMM). Cardiac toxicities have been reported with the use of carfilzomib. We aimed to determine the overall incidence and risk of cardiac toxicities in RRMM patients treated with carfilzomib using a meta-anal...
Autores principales: | Zhao, Fang, Yang, Bo, Wang, Juan, Zhang, Rui, Liu, Jing, Yin, Fenglei, Xu, Weixing, He, Chunyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985801/ https://www.ncbi.nlm.nih.gov/pubmed/29881259 http://dx.doi.org/10.2147/DDDT.S159818 |
Ejemplares similares
-
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015) -
Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019) -
The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021) -
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
por: Fostier, Karel, et al.
Publicado: (2012) -
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)